IDRX-42 continues to demonstrate promising anti-tumor activity with a 29% ORR across all patients (median four prior lines of therapy) and a 53% objective response rate (ORR) in second-line patients ...
WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, a clinical-stage biopharmaceutical company advancing two Phase 2 small-molecule programs for immunological, inflammatory, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results